Madison Square Garden Sports (NASDAQ: MSGS) shares closed at $384.68, marking a new 52-week high on Friday despite ongoing deterioration in reported earnings, as investors increasingly value the company on the embedded worth of its NBA and NHL franchises.

 

Key Highlights

 

  • MSGS stock declined 2.29% on the day but still registered a new 52-week high intraday, with volume of 429,000 shares reflecting above-average investor activity at the $9.3 billion market cap level.
  • Trailing diluted EPS has deteriorated sharply year-on-year due to elevated operating costs, yet the stock continues to attract buyers who price the Knicks and Rangers franchises well above book value.

 

Madison Square Garden Sports stock is one of the more unusual cases in US equity markets, where reported earnings metrics have little bearing on market valuation. The New York Knicks and New York Rangers are among the most valuable franchises in their respective leagues, with independent valuations that significantly exceed what the balance sheet reflects.

 

The company's market cap of over $9.2 billion implies a per-franchise valuation that is consistent with recent NBA and NHL transaction comparables. As sports franchise ownership becomes an increasingly sought-after asset class for institutional and family office investors, MSGS offers listed equity exposure to an otherwise private market.

 

For investors evaluating MSGS stock as a sports franchise investment, the key metric is not earnings per share but rather franchise appreciation. Major US sports team values have compounded at a pace that has historically outpaced the broader equity market over multi-decade periods.

 

The stock's new 52-week high, achieved despite a down day, reflects the market's focus on potential corporate events including a partial or full franchise monetisation. Best sports franchise stocks for 2026 are drawing increased attention as media rights negotiations across the NBA and NHL drive asset repricing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.